Drug Trial Radar · NCT06075095
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
297
Actual
Start
Jan 11, 2024
Primary completion
Aug 12, 2025
Study completion Aug 12, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: 1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing 2. Three treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) 3. A final safety follow-up visit via telephone contact approximately 1 to 2 weeks after the final dose administration Participants will be provided with rescue SABA (albuterol or salbutamol) to be used as needed throughout the study. Participants will attend in-clinic study visits approximately weekly during the screening/run-in period (Visits 1, 2, and 3), then every 4 weeks (Visits 4, 5, and 6) to receive take-home study treatment, measure their lung function, and assess their health and safety
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μgDrug
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
BGF MDI HFA 320/14.4/9.6 μgDrug
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
Placebo MDI HFADrug
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in FEV1 AUC (0-4)Time frame: Change from baseline at Day 29
- Change in morning pre-dose trough FEV1Time frame: Change from baseline at Day 29
- Changes in FEV1 AUC (0-4)Time frame: Change from baseline at Day 29
- Change in morning pre-dose trough FEV1Time frame: Change from baseline at Day 29
Locations
87 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Sheffield, Alabama
Research Site
Clearwater, Florida
Research Site
Gainesville, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Tampa, Florida
Research Site
Rincon, Georgia
Research Site
Chicago, Illinois
Research Site
Saint Charles, Missouri
Research Site
St Louis, Missouri
Research Site
The Bronx, New York
Research Site
Raleigh, North Carolina
Research Site
Dublin, Ohio
Research Site
Medford, Oregon
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Gaffney, South Carolina
Research Site
Boerne, Texas
Research Site
El Paso, Texas
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Quilmes, Argentina
Research Site
Rosario, Argentina
Research Site
San Fernando, Argentina
Research Site
Burgas, Bulgaria
Research Site
Pernik, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vratsa, Bulgaria
Research Site
Truro, Nova Scotia, Canada
Research Site
Burlington, Ontario, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saint-Charles-Borromée, Quebec, Canada
Research Site
Balassagyarmat, Hungary
Research Site
Hajdúnánás, Hungary
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.